The TCGA discovery on the defects in the HR pathway commonly existed in more than 50% of high-grade serous ovarian cancers [25], had led to further investigation of PARP inhibitors in a wider population of ovarian cancers. This evidence concerns the gene PARP1 and ovarian cancer.